Identifications small molecules inhibitor of p53-mortalin complex for cancer drug using virtual screening by Utomo, Didik H et al.
open access  www.bioinformation.net Hypothesis
  Volume 8(9)   
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 8(9): 426-429 (2012)  426   © 2012 Biomedical Informatics
 
Identifications small molecules inhibitor of p53-
mortalin complex for cancer drug using virtual 
screening 
 
 
Didik H Utomo, Widodo* & M Rifa’i 
 
 
Biology Department, Faculty of Sciences, Brawijaya University, Malang, Indonesia; Widodo - E-mail: widodo@ub.ac.id; Phone: 
+62-3140691, +62-341-575841; *Corresponding author 
 
 
Received April 08, 2012; Accepted April 27, 2012; Published May 15, 2012 
 
 
Abstract: 
Mortalin was over expressed in tumor cells and bind to p53 protein. This interaction was suggested to promote sequestration of 
p53 in the cytoplasm, thereby inhibiting its nuclear activity. The p53     is a tumor suppressor that is essential for the prevention of 
cancer development and loss of p53 function is one of the early events in immortalization of human cells. Therefore, abrogation 
p53-mortalin interaction using small molecule is guaranteed stop cancer cell grow. However study interaction of p53-mortalin, and 
its inhibition using small molecule is still challenging because specific site of mortalin that bind to p53, vice versa, is still debatable. 
This study has aims to analyze the p53-binding site of mortalin using molecular docking and to screen drug-like compounds that 
have potential as inhibitors of p53-mortalin interaction using virtual screening. The result showed that the lowest energy binding of 
p53-mortalin complex is -31.89 kcal/mol, and p53 protein bind to substrate binding domain of mortalin (THR433; VAL435; 
LEU436; LEU437; PRO442; ILE558; LYS555). Furthermore, the p53-binding domain of mortalin was used as receptor to screen  9000 
drug-like compounds from ZINC database using molecular docking program Auto Dock Vina in PyRx 0.8 (Virtual Screening 
Tools). Here, we have identified three drug-like compounds that are ZINC01019934, ZINC00624418 and ZINC00664532 adequate to 
interrupt stability of p53-mortalin complex that warrant for anticancer agent.                                      
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Background: 
Protein–protein interactions (PPIs) are essential components of 
all biological processes such as oncogenesis [1]. Several 
observations suggested that mortalin is involved in the 
transformation of normal cells to cancer-cells [2], which 
mortalin interacted with p53 that promotes sequestration of p53 
in the cytoplasm, thereby inhibiting its nuclear activity [3] and 
induce the resistance of tumors in radiotherapy and 
chemotherapy. Mortalin changes its sub-cellular location from 
mitochondria of normal cells to cytosol, of cancerous cells [4]. 
Protein of p53, the “guardian of the genome,” is a major player 
in cell cycle arrest and apoptosis in response to the diverse 
endogenous and exogenous stress signals [5]. The p53      is a 
tumor suppressor that is essential for the prevention of cancer 
development [6]   .   Loss of p53 function is one of the early events 
in immortalization of human cells [7]. Another function of p53, 
independent to its nuclear localization, is to regulate 
mitochondrial membrane potential by interactions with the 
mitochondrial proteins bcl2 and mortalin [8]. Furthermore 
inhibition of p53-mortalin complex using small molecule is 
promising strategy to find drug materials for cancer therapy 
since the small molecules able to inhibit interaction between 
two proteins [9]. However study interaction p53-mortalin and 
its inhibition using small molecule is still challenging because 
s p e c i f i c  s i t e  o f  m o r t a l i n  t h a t  b i n d  t o  p 5 3 ,  v i c e  v e r s a ,  i s  s t i l l  
debatable. Experimental analysis by truncated protein 
recombinant suggested that mortalin-binding site of p53 was 
localized to the tetramerization domain, namely amino acids BIOINFORMATION  open access 
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323–337 residues [5]. Conversely, the binding site for p53 on 
mortalin was mapped to amino acids 253–282 residues, in the 
ATPase domain [10]. Otherwise Iosefson demonstrated that p53 
binds to the peptide-binding domain of mortalin and not to the 
ATP-binding site of mortalin [11]. P53 harbors two binding sites 
for mortalin. The first one was previously determined to be in 
the tetramerization domain [5], and the second is found in the 
C-terminal domain [11].  Moreover we elucidated the binding 
site in both of the protein (p53 and mortalin) by molecular 
docking method. The docking method was powerful to predict 
specific binding site of protein-protein complex [12]. Here we 
demonstrated that mortalin-binding site of p53 reside in 326 to 
341 residues, and p53-binding site of mortalin hold in range 423 
to 450 residues. Based on the binding activity, then we analyzed 
its binding stability when been interfered with small molecule 
to obtain drug candidate for cancer therapy. Furthermore we 
identified small molecules inhibitor of p53-mortalin complex. 
Here we found 3 drug-like compounds from Zinc database that 
potentially abrogate p53-mortalin interaction using Virtual 
Screening.                                                    
 
Methodology: 
Retrieval of Target Sequence 
The amino acid sequence of mortalin ID: NP_000537.3 was 
obtained from the sequence database of NCBI 
(http://www.ncbi.nlm.nih.gov), and model of p53 (1AIE) was 
from PDB BANK (http://www.rscb.org).    
 
Modeling proteins mortalin  
The tertiary structure of mortalin is not available in the protein 
structure databases, and then the structure was predicted by 
comparative modeling using MODELLER (PS2 Server) [13]. The 
predicted three dimension (3D) structures were validated using 
the PROCHECK to evaluate backbone conformation based on 
Psi/Phi Ramachandran plot analysis. 
 
Docking protein – protein 
We used cons-PPISP to predict a site for interaction of p53 and 
mortalin. The input is the unbound structure of a protein, which 
is known to bind another protein [14]. Then we used the 
PatchDock algorithm (rigid docking) to compute possible 
interaction p53 with mortalin based on its interaction site. 
Output of rigid docking was refined using FireDock. FireDock 
refines the candidate models according to an energy function 
[15]. Thereafter, we used FiberDock software to simulate most 
possible native complex structure of mortalin-p53 in flexible 
mode, which are include both backbone and side-chains 
movements [16].  
 
Ligand Preparation  
About 9000 drug-like compounds were downloaded from zinc 
database (http://zinc.docking.org), then its energy form were 
minimized and converted to pdbqt format by Open Babel in 
PyRx 0.8 [12] as ligand for virtual screening. 
 
Virtual Screening 
Identifications small molecules targeted mortalin was done by 
docking of the entire 9000 drug-like  compounds from  ZINC 
database against p53-binding domain of mortalin using 
A u t o D o c k  V i n a  i n  P y R x  0 . 8  (Virtual Screening Tools) [12]. 
Virtual screening is now established as an effective paradigm 
for filtering compounds for drug discovery process [17]. The 
grid for docking calculations was centered on p53-binding 
domain of mortalin. The best three of drug-like compounds 
from virtual screening were taken on the basis of higher scoring 
function for pharmachopore modeling, which is one of the most 
powerful techniques to classify and identify key features from a 
group of molecules. LigandScout was used to develop 
pharmacophore and molecular interaction of these three drug-
like.  
 
Molecular Dynamics Simulation 
The binding stability of p53-mortalin complex before and after 
interference by the small molecules was simulated using 
GroGUI 0.5.2 version of GROMACS MD simulation package. 
The first steps are preparation of the atomic and topology of 
ligand, receptor and the small molecules. Second steps are 
made box water for simulation and then energy minimization is 
performed in order to eliminate potential geometric problems in 
the protein and ligand structures, such as unrealistic bond 
distances, bond angles and torsion angles. Next step involved 
the equilibration of the solute molecules with a fixed 
configuration of the solvent molecules in which the system was 
heated 300K with Berendsen temperature coupling and 
Pressure coupling with Parrinello-Rahman (isotropic). The 
Particle Mesh Ewald (PME) method was used to treat long-
range electrostatic interactions. The coordinates of the trajectory 
was sampled every 2.5 ps for analysis of the energy stabilization 
Plots for potential energy, RMSD fluctuations, involving p53-
mortalin and other complexes [18].  
 
 
Figure 1: 3D model of mortalin. 
 
Visualization 
All the visualization of the structure files were done using 
PyMol molecular graphics system (www.pymol.org). 
 
Discussion: 
Designing anti-cancer drug targeted p53 protein [19] or p53 
binding-domain of mortalin is very promising [10]. However 
the p53-binding site of mortalin still debatable [5] [10], then we 
analyzed the binding site based on their interaction using 
molecular docking. Since the three dimensions (3D) structure of 
mortalin was still not available yet then we used 3D model of 
mortalin to determine it’s binding to p53 protein. Model 3D of 
mortalin was determined by comparative modeling using 
MODELLER (PS2 Server). The quality and reliability of the 
model was ensured by assessing the backbone conformation, BIOINFORMATION  open access 
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angels and bond lengths based on Psi/Phi Ramachandran plot 
using PROCHECK, it showed a total of 93.7% residues in the   
most favored   regions (Figure 1).  
 
 
Figure 2: p53-mortalin complex. p53 (red color) binds to 
mortalin (blue color) on Substrate Binding Domain (THR433; 
VAL435; LEU436; LEU437; PRO442; ILE558; LYS555). 
 
Furthermore, we used the valid model to analyze p53-binding 
site of mortalin based on the flexible docking. The  result 
showed that the lowest energy binding of p53-mortalin complex 
is -31.89 kcal/mol, and p53 protein bind to substrate binding 
domain of mortalin (THR433; VAL435; LEU436; LEU437; 
PRO442; ILE558; LYS555) (Figure 2). The result suggested that 
mortalin-binding site of p53 reside in 326 to 341 residues, in 
accordance with opinion Kaul et al (1998) [5], and p53-binding 
site of mortalin in  423 to 450 residues that it strengthens 
Iosefson data (2010) [11].  
 
Figure 3: The best three small molecules bind to p53-binding 
site of mortalin (ZINC01019934, ZINC00624418, and 
ZINC00664532). 
 
 
Figure 4: Ligands bind to complex p53-mortalin.  A.   
ZINC01019934 blocks amino acid LEU 350 and ALA 353 of p53 
protein and blocks amino acid PRO 442 and ILE 558 of mortalin 
protein. B. ZINC00624418 blocks amino acid LEU 350 and ALA 
353 of p53 protein and blocks amino acid LEU 437 and PRO 442 
of mortalin protein. C. ZINC00664532 blocks amino acid LEU 
350 and ALA 353 of p53 and blocks amino acid PRO 442 and 
ILE 558 of mortalin. BIOINFORMATION  open access 
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The p53-binding domain of mortalin was used as receptor to 
screen 9000 drug-like compounds (small molecules) from ZINC 
database. The screening was performed using molecular 
docking program AutoDock Vina in PyRx 0.8 (Virtual Screening 
Tools) [12]. The virtual screening obtained the best three drug-
like molecules that are ZINC01019934, ZINC00624418 and 
ZINC00664532, which are require smaller energy than other 
molecules to bind with mortalin (Figure 3). These data 
indicated that the three molecules were able bond strongly to 
p53-binding site of mortalin and its binding will inhibit p53 
protein interact to mortalin. Then we evaluated interaction of 
the three molecules to the p53-mortalin complex by docking 
followed with ligandscout. The result demonstrated that the 
three molecules bound to amino acid in center of the active site 
of both mortalin and p53, which are essential for establishment 
p53-mortalin complex (Figure 4). Hereafter, we evaluated the 
binding stability of the three molecules to p53-mortalin complex 
using GroGUI 0.5.2 version of GROMACS molecular dynamics 
(MD) simulation package [18]. MD simulations have provided 
detailed information on the fluctuations and conformational 
changes in protein complex [20].  
 
 
Figure 5: The stability of p53-mortalin complexes. A. Energy 
stability of p53-mortalin complex (black line) increase after 
added the small molecules (blue, red and green line). B. RMSD 
of p53-mortalin complex (black line) has more unstable after 
interfered with the small molecules (green, blue and red line). 
The red color indicates ZINC01019934, green is ZINC00624418, 
and blue is ZINC00664532. 
The simulation described that the three molecules interrupted 
stability of p53-mortalin complex. This is indicated by an 
increase binding energy of mortalin-p53 complex and root 
mean square deviations (RMSD) of the protein complexes have 
changed significantly after added with the small molecule 
(Figure 5). Taken together the results suggested that the three 
molecules have potency to abrogate p53-mortalin interaction 
that warrant for anticancer agent. Therefore further experiment 
to examine its activities in vitro and in vivo to cure cancer is still 
shall to be done. 
 
Conclusion: 
These studies could be concluded that p53-binding site of 
mortalin reside in substrate binding domain, 423 to 450 
residues. We have identified three drug-like molecules that are 
ZINC01019934, ZINC00624418 and ZINC00664532 adequate to 
interrupt stability of p53-mortalin complex that warrant for 
anticancer agent.  
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